Last Updated: Apr 30, 2016
- Mutational analysis of FANCJ helicase.
Guo Manhong, et al. Methods (San Diego, Calif.) 2016 4 - Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Myers Meagan B, et al. Neoplasia (New York, N.Y.) 2016 4 (4) 253-63 - Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic.
Borecka M, et al. Cancer genetics 2016 4 - The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Bombard Yvonne et al. The oncologist 2015 Apr 20(4) 351-6 - A Bioinformatics approach for precision medicine Off-Label drug selection among triple negative breast cancer patients.
Cheng Lijun et al. Journal of the American Medical Informatics Association : JAMIA 2016 Apr - Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
Kopp Tine Iskov, et al. BMC cancer 2016 0 (1) 283 - Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer.
Dalin Martin G, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 4 - In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani Silvia, et al. Virchows Archiv : an international journal of pathology 2016 4 - Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman Natalia, et al. Clinical pharmacokinetics 2016 4 - PALB2: research reaching to clinical outcomes for women with breast cancer.
Southey Melissa C, et al. Hereditary cancer in clinical practice 2016 0 9 - Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study.
Koleck Theresa A, et al. SpringerPlus 2016 0 422 - Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities.
Heilmann Thorsten, et al. Archives of gynecology and obstetrics 2016 4 - Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller Kristen E, et al. Experimental and molecular pathology 2016 4 (3) 421-425 - A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer.
Bolton Katherine A, et al. Endocrine connections 2016 4 - Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André Fabrice, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 4 - Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer.
Shi Jiajun, et al. International journal of cancer 2016 4 - Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
Evans D G, et al. Hereditary cancer in clinical practice 2016 0 8 - Characteristics, Malignancy Rate, and Follow-up of BI-RADS Category 3 Lesions Identified at Breast MR Imaging: Implications for MR Image Interpretation and Management.
Chikarmane Sona A, et al. Radiology 2016 4 151548 - Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera Milagros, et al. Breast cancer research and treatment 2016 4 (3) 507-15 - Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model
Lee AJ, et al. Genetics in Medicine (2016) April 14 - Identification of Novel BRCA Founder Mutations in Middle Eastern Breast Cancer Patients Using Capture and Sanger Sequencing Analysis.
Bu Rong, et al. International journal of cancer 2016 4 - Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study.
Falanga Anna, et al. Thrombosis research 2016 4 S55-9 - A Meta-Analysis of the Association between ESR1 Genetic Variants and the Risk of Breast Cancer.
Li Taishun, et al. PloS one 2016 0 (4) e0153314 - Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.
Yang Fang, et al. Oncology letters 2016 4 (4) 2481-2486 - DNA repair variants and breast cancer risk.
Grundy Anne, et al. Environmental and molecular mutagenesis 2016 5 (4) 269-81 - Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Drooger Jan C, et al. Breast cancer research and treatment 2016 4 - High body mass index and cancer risk-a Mendelian randomisation study.
Benn Marianne, et al. European journal of epidemiology 2016 4 - Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer.
Huynh Julie M, et al. Molecular genetics & genomic medicine 2016 3 (2) 232-6 - Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
Saha Soumi, et al. Indian journal of surgical oncology 2015 12 (4) 378-83 - Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
Evans Chalanda N et al. Breast cancer research and treatment 2016 Apr
- Human (0)
- Pathogen (1)
- Human (5157)
- Pathogen (0)
- Human (405)
- Pathogen (0)
No hay comentarios:
Publicar un comentario